Both the regulators in UK and EU have ruled out the connection between Oxford-AstraZeneca vaccine and blood clotting. As a result, several countries have started the vaccination process with the Oxford-AstraZeneca vaccine once again following to temporary pause due to concerns over its impact on health.

What has been advised regarding blood clot?

Evidence has not been found yet that Oxford-AstraZeneca vaccine is unsafe. Reports have been received that very small number of people has suffered from blood following to the immunization. Cases of blood clot are very rare that too in the brain. In UK, there are about 5 cases. So, there is about one case from 11 million that have already received the vaccine.
By the European Medicine Agency, 13 cases of blood clotting have been reported. Cases of blood clotting may have happened due to some another cause. The vaccine may not be linked with the condition at all.
Later on, a thorough review has been done by EMA and it has given confidence to the people to take the vaccine without any worries. Benefits of the vaccine must be enjoyed.
However, precautions have been taken by the regulators certainly as they are still monitoring the condition very closely. It has been advised to consult with the doctors if there is any kind of unusual bruising and severe headache is experienced after the vaccination process.
In case of serious COVID-19 infection, clots are seen sometimes.

How does the vaccine function?

Oxford-AstraZeneca vaccine is created out of cold virus of weaker nature from chimpanzees. Later on, it has been modified further to deal with the coronavirus. However, it cannot make you ill.
Following to the vaccine jab, immune system of the body is activated to battle with the virus. To store Oxford-AstraZeneca vaccine, extreme cold temperature is not required. Therefore, the vaccine can be stored easily in the fridge. Distribution process of vaccine has become easier as result.

How much Oxford-AstraZeneca vaccine is effective in comparison to Pfizer?

Through trials, it has been seen that Pfizer vaccines offers 95% efficacy. However, Oxford-AstraZeneca vaccine is only effective by 62%.
However, it is hard to compare both the vaccines as there have been differences in the trial process also.
Following to the immunization with the Oxford-AstraZeneca vaccine, no one has become seriously ill or hospitalized.
Recent studies have shown, single dose of Oxford-AstraZeneca vaccine offers 76% of protection for about three months. Post the second dose; it can go up to 82%.

Should elderly people take the vaccine?

In the beginning, vaccines have been given to people between 18 and 64 years in the European Union as there has been very limited data present regarding its protection level on the people at the age of 65 or above.
Later on, France and Germany has reversed their standpoint regarding this matter and approved the vaccine for the people above the age of 65.